SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

28 Jan 2025 Evaluate
The revenue for the December 2024 quarter is pegged at Rs. 49708.80 millions, about 13.46% up against Rs. 43813.30 millions recorded during the year-ago period.A comparatively good net profit growth of 41.31% to Rs. 14381.50 millions was reported for the quarter ended December 2024 compared to Rs. 10177.60 millions of previous same quarter.The company reported a good operating profit of 18505.20 millions compared to 15248.40 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 49708.80 43813.30 13.46 142469.60 125376.70 13.63 165743.40 143453.40 15.54
Other Income 1886.90 1689.80 11.66 6913.50 5320.50 29.94 10706.60 4567.90 134.39
PBIDT 18505.20 15248.40 21.36 51510.80 41895.00 22.95 55548.10 38096.80 45.81
Interest 35.50 90.60 -60.82 116.20 159.80 -27.28 202.50 222.70 -9.07
PBDT 18469.70 15157.80 21.85 51394.60 41735.20 23.14 55345.60 36015.10 53.67
Depreciation 1426.20 1350.20 5.63 4261.90 4507.80 -5.45 5875.90 5959.10 -1.40
PBT 17043.50 13807.60 23.44 47132.70 37227.40 26.61 49469.70 30056.00 64.59
TAX 2662.00 3630.00 -26.67 10410.20 9905.60 5.09 12327.80 8615.40 43.09
Deferred Tax 32.40 143.10 -77.36 134.10 40.60 230.30 60.90 -400.90 -115.19
PAT 14381.50 10177.60 41.31 36722.50 27321.80 34.41 37141.90 21440.60 73.23
Equity 1615.20 1614.70 0.03 1615.20 1614.70 0.03 1614.70 1614.30 0.02
PBIDTM(%) 37.23 34.80 6.97 36.16 33.42 8.20 33.51 26.56 26.20

Cipla Share Price

1230.00 1.10 (0.09%)
21-Apr-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.95
Dr. Reddys Lab 1242.75
Cipla 1230.00
Zydus Lifesciences 935.00
Lupin 2337.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×